Conexeu Sciences Inc.
Conexeu Sciences Inc.
- Market cap
- $47.79M
Your view on CNXU
Overview
What the company does, where it operates, and who runs it.
About Conexeu Sciences Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Miles Harrison
- Headquarters
- 50 W Liberty St, Suite 880, Reno, NV, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Miles Harrison
- Headquarters
- 50 W Liberty St, Suite 880, Reno, NV, US
Conexeu Sciences Inc. specializes in pioneering regenerative biomaterials intended for various medical fields, including wound management, dental practices, and aesthetic medicine. The enterprise began operations on November 2, 2022, co-founded by Claudia Chavez-Munoz, David R.
Bogart, and Ryan Hartwell, and operates from its primary office in Reno, Nevada.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Conexeu Sciences Inc.. Starting points for Conexeu Sciences Inc.: EPS -$0.20, beta 0.51 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Conexeu Sciences Inc.. Trailing twelve-month EPS for Conexeu Sciences Inc. stands at -$0.20. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Conexeu Sciences Inc.. Conexeu Sciences Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| INDPIndaptus Therapeutics, Inc. | Healthcare | NASDAQ | $319.3M | ||
| INFIQInfinity Pharmaceuticals, Inc. | Healthcare | OTC | $9,076 | ||
| INKTMiNK Therapeutics, Inc. | Healthcare | NASDAQ | $41.2M | ||
| INMBINmune Bio, Inc. | Healthcare | NASDAQ | $25.6M | ||
| INNMFAmplia Therapeutics Limited | Healthcare | OTC | $30.8M | ||
| INOInovio Pharmaceuticals, Inc. | Healthcare | NASDAQ | $121.6M | ||
| GLOW.CNGlow Lifetech Corp. | Healthcare | CNQ | $10.9M | ||
| GLPGFGalapagos N.V. | Healthcare | OTC | $2.2B | ||
| GLSHQGelesis Holdings, Inc. | Healthcare | OTC | $7,334 | ||
| GLSIGreenwich LifeSciences, Inc. | Healthcare | NASDAQ | $282.6M | ||
| GLTOGalecto, Inc. | Healthcare | NASDAQ | $34.5M | ||
| GLUEMonte Rosa Therapeutics, Inc. | Healthcare | NASDAQ | $738.3M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Conexeu Sciences Inc. executives and directors. Shares of Conexeu Sciences Inc. have traded between $7.10 and $18.79 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Conexeu Sciences Inc.. Coverage tracks Conexeu Sciences Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Conexeu Sciences Inc.